What topics does this cannabis study cover?

This study covers research on: Inflammation, CBD.

CBD shows promise against diabetic heart disease in early research

Q: What did this Review find?

Cannabidiol (*CBD*) shows significant promise as a **multi-target therapeutic agent** for diabetic heart disease (*DHD*), a leading cause of heart problems in people with diabetes worldwide. Preclinical research demonstrates that *CBD* works through several interconnected mechanisms: it reduces harm

Q: Where was this research published?

Published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie on May 1, 2026.

Cannabidiol and diabetic heart disease: Mechanistic evidence and translational challenges.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie • May 1, 2026 • Review • Moderately Relevant

🤖

AI Summary

Cannabidiol (CBD) shows significant promise as a multi-target therapeutic agent for diabetic heart disease (DHD), a leading cause of heart problems in people with diabetes worldwide. Preclinical research demonstrates that CBD works through several interconnected mechanisms: it reduces harmful reactive oxygen species (ROS) that damage heart cells, suppresses NF-κB-mediated inflammatory signaling, improves blood vessel function by enhancing nitric oxide bioavailability, and prevents fibrotic remodeling of the heart. These effects address multiple core pathways that current cardiometabolic medications cannot fully tackle, making CBD a uniquely broad potential intervention for a complex disease.

The evidence supporting CBD comes from extensive laboratory and animal studies, where it has consistently improved both heart muscle and blood vessel function in diabetic models. CBD achieves these benefits through negative allosteric modulation of CB₁ receptors and interaction with several non-cannabinoid targets, including TRPV1, PPAR-γ, and GPR55. However, a critical gap exists: human clinical evidence remains limited. Most existing studies are either conducted in non-diabetic populations or focus only on short-term metabolic outcomes rather than actual heart disease endpoints in diabetic patients.

Before CBD can be recommended for diabetic heart disease, researchers must overcome significant translational challenges including variable dosing, inconsistent product standardization, and potential drug-drug interactions. Well-designed clinical trials specifically targeting diabetic populations and measuring disease-relevant cardiac outcomes are essential to establish safety and efficacy. While the mechanistic foundation is robust and compelling, CBD remains an investigational candidate awaiting rigorous human evidence before clinical implementation becomes feasible.

📄 Original Abstract

Diabetic heart disease (DHD) is a major contributor to global cardiovascular morbidity, driven by a complex interplay of metabolic, inflammatory, oxidative, and fibrotic mechanisms. These interconnected pathways are not fully addressed by current cardiometabolic therapies, highlighting the need for novel multi-target interventions. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, has emerged as a potential modulator of several key processes implicated in DHD pathogenesis. Preclinical evidence demonstrates that CBD attenuates oxidative stress by reducing reactive oxygen species (ROS) production, suppresses nuclear factor-κB (NF-κB)-mediated inflammatory signaling, preserves endothelial function by improving nitric oxide (NO) bioavailability, and inhibits transforming growth factor-β (TGF-β)-driven fibrotic remodeling. These effects have been observed across in vitro and in vivo models of diabetic cardiomyopathy, where CBD improves both myocardial and vascular function. Mechanistically, CBD exerts its actions through negative allosteric modulation of CB₁ receptors and interaction with non-cannabinoid targets, including transient receptor potential vanilloid 1 (TRPV1), peroxisome proliferator-activated receptor gamma (PPARγ), and G protein-coupled receptor 55 (GPR55). Despite this robust preclinical foundation, clinical evidence supporting the efficacy of CBD in DHD remains limited. Existing human studies are largely restricted to non-diabetic populations or short-term metabolic and hemodynamic outcomes, and do not address disease-specific cardiac endpoints. Furthermore, translational challenges, including variability in dosing, product standardization, and potential drug-drug interactions, remain significant barriers to clinical implementation. Collectively, CBD represents a promising investigational candidate with multi-target potential to modulate the core pathophysiology of DHD. However, well-designed, disease-specific clinical trials are required to establish its therapeutic relevance and safety in diabetic populations.

Paper Type

📚 Review

Publication

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 1, 2026
PMID: 41966803
DOI: 10.1016/j.biopha.2026.119354

Authors (7)

Afolake Arowolo Biomedical Research and Innovation Platform (BRIP), South African Medical Research Council (SAMRC), Cape Town, Western Cape, South Africa; Department of Medicine, University of Cape Town, Cape Town, Western Cape, South Africa. Electronic address: Afolake.Arowolo@mrc.ac.za.
Oluyomi Adeyemi Department of Biochemistry, Bowen University, Iwo, Osun State, Nigeria.
Toluwalope Ajonijebu Department of Biochemistry, North-West University, Potchefstroom, North-West, South Africa.
Aminu Musa Department of Physiology, Nelson Mandela University, Gqeberha, Eastern Cape, South Africa.
Hygon Mutavhatsindi Biomedical Research and Innovation Platform (BRIP), South African Medical Research Council (SAMRC), Cape Town, Western Cape, South Africa; Department of Medicine, University of Cape Town, Cape Town, Western Cape, South Africa.
+2 more authors